Review
Immunology
Paul Curtiss, Amanda M. Walker, Benjamin F. Chong
Summary: This study reviewed patient cohorts and populations to investigate the progression of cutaneous lupus to systemic lupus. The study found variations in the progression rates between adult and pediatric groups, which were attributed to differences in patient populations, study design, diagnostic criteria, and follow-up time. Risk factors associated with the development of systemic lupus included positive anti-nuclear antibodies, hematologic abnormalities, and a higher number of lupus classification criteria at baseline.
FRONTIERS IN IMMUNOLOGY
(2022)
Review
Immunology
Qian Chen, Jie Wang, Mengmeng Xiang, Yilun Wang, Zhixiong Zhang, Jun Liang, Jinhua Xu
Summary: This review summarizes the potential links between ferroptosis and systemic lupus erythematosus (SLE), elucidates the role of ferroptosis in SLE pathogenesis, and proposes a new therapeutic strategy for SLE.
FRONTIERS IN IMMUNOLOGY
(2022)
Review
Medicine, General & Internal
Jae Il Shin, Keum Hwa Lee, Seoyeon Park, Jae Won Yang, Hyung Ju Kim, Kwanhyuk Song, Seungyeon Lee, Hyeyoung Na, Yong Jun Jang, Ju Yun Nam, Soojin Kim, Chaehyun Lee, Chanhee Hong, Chohwan Kim, Minhyuk Kim, Uichang Choi, Jaeho Seo, Hyunsoo Jin, BoMi Yi, Se Jin Jeong, Yeon Ook Sheok, Haedong Kim, Sangmin Lee, Sangwon Lee, Young Soo Jeong, Se Jin Park, Ji Hong Kim, Andreas Kronbichler
Summary: Systemic lupus erythematosus (SLE) is a complex autoimmune disease with various manifestations, including pleuropulmonary involvement. The precise mechanism of pleuropulmonary involvement in SLE is not well-understood, but type 1 interferons, immune complexes, and neutrophils likely play important roles. There are multiple types of pleuropulmonary involvement, and various diagnostic tools and immunosuppressive therapies are used. However, specific therapies for pleuropulmonary involvement in SLE remain limited.
JOURNAL OF CLINICAL MEDICINE
(2022)
Review
Immunology
Swayanka Biswas, Katja Bieber, Rudolf Armin Manz
Summary: IL-10 is a cytokine that has pleiotropic effects on immune cells, including both suppressive and activating functions. It plays a dual role in Systemic lupus Erythematosus (SLE), inhibiting pro-inflammatory effector functions while also promoting extrafollicular antibody response. IL-10 is produced by B cells, myeloid cells, and certain T cell subsets, and it drives B cell responses, proliferation, class switching, and plasma cell formation.
FRONTIERS IN IMMUNOLOGY
(2022)
Review
Biochemistry & Molecular Biology
Madhu Ramaswamy, Raj Tummala, Katie Streicher, Andre Nogueira da Costa, Philip Z. Brohawn
Summary: Systemic lupus erythematosus (SLE) presents a challenging treatment landscape due to its multifaceted etiology and complex immunopathogenesis. While targeting the B-cell pathway has limitations, recent approval of anifrolumab, a type I interferon-blocking antibody, highlights the therapeutic potential of targeting the dysregulated interferon pathway in SLE patients. Further research into the pleiotropic biology of interferons and their intersection with SLE disease pathology will be crucial for the development of effective targeted therapies.
INTERNATIONAL JOURNAL OF MOLECULAR SCIENCES
(2021)
Review
Rheumatology
Mary K. Crow
Summary: Research has identified type I interferon (IFN-I) and autoantibodies targeting nucleic acids and nucleic acid-binding proteins as fundamental contributors to the pathogenesis of systemic lupus erythematosus (SLE). This review summarizes recent genetic analyses of SLE patients and current studies on innate and adaptive immune function, which contribute to sustained IFN-I pathway activation, immune activation, autoantibody production, inflammatory mediator generation, and tissue damage. The goal of these studies is to understand disease mechanisms, identify therapeutic targets, and develop better treatments for patients.
ANNALS OF THE RHEUMATIC DISEASES
(2023)
Article
Rheumatology
May Yee Choi, Ann Elaine Clarke, Murray Urowitz, John Hanly, Yvan St-Pierre, Caroline Gordon, Sang-Cheol Bae, Juanita Romero-Diaz, Jorge Sanchez-Guerrero, Sasha Bernatsky, Daniel J. Wallace, David Isenberg, Anisur Rahman, Joan T. Merrill, Paul R. Fortin, Dafna D. Gladman, Ian N. Bruce, Michelle Petri, Ellen M. Ginzler, Mary Anne Dooley, Rosalind Ramsey-Goldman, Susan Manzi, Andreas Jonsen, Graciela S. Alarcon, Ronald F. van Vollenhoven, Cynthia Aranow, Meggan Mackay, Guillermo Ruiz-Irastorza, Sam Lim, Murat Inanc, Ken Kalunian, Soren Jacobsen, Christine Peschken, Diane L. Kamen, Anca Askanase, Jill P. Buyon, Karen H. Costenbader, Marvin J. Fritzler
Summary: In a longitudinal analysis of a large international incident SLE cohort, three ANA assays demonstrated high positivity rates and commutability. However, over a 5-year follow-up, there was a modest variation in ANA assay performance.
ANNALS OF THE RHEUMATIC DISEASES
(2022)
Review
Immunology
Wei Sun, Pengchong Li, Jianping Cai, Jie Ma, Xuan Zhang, Yong Song, Yudong Liu
Summary: This article summarizes the altered lipid metabolism and its role in the pathogenesis and progression of SLE. Dysregulated lipid metabolism has complex effects on specific cell types, and may serve as a potential therapeutic target.
FRONTIERS IN IMMUNOLOGY
(2022)
Review
Chemistry, Medicinal
Przemyslaw Kotyla, Olga Gumkowska-Sroka, Bartosz Wnuk, Kacper Kotyla
Summary: Systemic sclerosis and systemic lupus erythematosus are two distinct autoimmune diseases belonging to connective tissue disorders, with no groundbreaking therapeutic approaches developed yet. The discovery of JAK kinases may offer a new therapeutic potential for previously untreatable diseases.
Article
Rheumatology
May Yee Choi, Irene Chen, Ann Elaine Clarke, Marvin J. Fritzler, Katherine A. Buhler, Murray Urowitz, John Hanly, Yvan St-Pierre, Caroline Gordon, Sang-Cheol Bae, Juanita Romero-Diaz, Jorge Sanchez-Guerrero, Sasha Bernatsky, Daniel J. Wallace, David Alan Isenberg, Anisur Rahman, Joan T. Merrill, Paul R. Fortin, Dafna D. Gladman, Ian N. Bruce, Michelle Petri, Ellen M. Ginzler, Mary Anne Dooley, Rosalind Ramsey-Goldman, Susan Manzi, Andreas Jonsen, Graciela S. Alarcon, Ronald F. van Vollenhoven, Cynthia Aranow, Meggan Mackay, Guillermo Ruiz-Irastorza, Sam Lim, Murat Inanc, Kenneth Kalunian, Soren Jacobsen, Christine Peschken, Diane L. Kamen, Anca Askanase, Jill P. Buyon, David Sontag, Karen H. Costenbader
Summary: A novel longitudinal clustering technique was used to analyze comprehensive autoantibody data from a large, well-characterised, multinational inception SLE cohort, in order to determine predictive profiles of clinical outcomes.
ANNALS OF THE RHEUMATIC DISEASES
(2023)
Article
Multidisciplinary Sciences
Kristian Juul-Madsen, Anne Troldborg, Thomas R. Wittenborn, Mads G. Axelsen, Huaying Zhao, Lasse H. Klausen, Stefanie Luecke, Soren R. Paludan, Kristian Stengaard-Pedersen, Mingdong Dong, Holger J. Moller, Steffen Thiel, Henrik Jensen, Peter Schuck, Duncan S. Sutherland, Soren E. Degn, Thomas Vorup-Jensen
Summary: Nanotechnology allows for the study of single biomacromolecules, and research has shown that the superoligomeric structure of MBL forms nanoparticles with DNA in human plasma. These oligomers are correlated with disease activity in patients with systemic lupus erythematosus, and their size is connected to endothelial inflammation. Insights from an animal model of lupus suggest that DNA-stabilized superoligomers play a role in the pathobiology of autoimmune diseases.
PROCEEDINGS OF THE NATIONAL ACADEMY OF SCIENCES OF THE UNITED STATES OF AMERICA
(2021)
Review
Pharmacology & Pharmacy
Xirui Guo, Xuerong Yang, Qi Li, Xiaoyan Shen, Huiyun Zhong, Yong Yang
Summary: Systemic lupus erythematosus (SLE) is a chronic diffuse connective tissue illness characterized by multisystem and multiorgan involvement. Intake of probiotics alters the composition of the gut microbiome, contributing to prevent the progression of SLE and alleviate symptoms in animal models. Probiotics supplementation may serve as a potentially novel approach in the treatment of SLE.
FRONTIERS IN PHARMACOLOGY
(2021)
Article
Oncology
Limin Liu, Longyuan Hu, Haojun Long, Meiling Zheng, Zhi Hu, Ye He, Xiaofei Gao, Pei Du, Hongjun Zhao, Di Yu, Qianjin Lu, Ming Zhao
Summary: The study identified IL21-AS1 as a regulator of Tfh cell differentiation and autoimmune response. Through epigenetic mechanisms, IL21-AS1 activates IL21 transcription to promote germinal center response, shedding light on the molecular regulation of autoimmune pathogenesis and providing a potential new target for treating SLE.
CLINICAL AND TRANSLATIONAL MEDICINE
(2022)
Article
Immunology
Morgane Humbel, Florence Bellanger, Alice Horisberger, Madeleine Suffiotti, Natalia Fluder, Mariko Makhmutova, Amandine Mathias, Renaud Du Pasquier, Craig Fenwick, Camillo Ribi, Denis Comte
Summary: This study identified an immune signature for systemic lupus erythematosus (SLE) based on the expression of signaling lymphocytic activation molecule family (SLAMF) receptors on peripheral blood mononuclear cells (PBMC). The frequency of SLAMF1+ B cells, SLAMF4+ monocytes, and SLAMF4+ NK showed correlations with disease activity. Consensus clustering analysis also identified two cell clusters, SLESMB and SLEcTFH, which were significantly increased in SLE compared to controls.
FRONTIERS IN IMMUNOLOGY
(2022)
Review
Immunology
Leonardo Martin Calderon, Janet E. Pope
Summary: The pathogenesis of connective tissue diseases involves immune system derangements, chronic inflammation, and autoimmunity. Pre-clinical states with biochemical and autoimmune abnormalities can increase the risk of developing established connective tissue diseases. Early identification and treatment in these states can limit disease progression and improve prognosis.
FRONTIERS IN IMMUNOLOGY
(2022)
Article
Rheumatology
Ronald F. van Vollenhoven, Bevra H. Hahn, George C. Tsokos, Peter Lipsky, Robert M. Gordon, Kaiyin Fei, Kim Hung Lo, Marc Chevrier, Shawn Rose, Pamela Berry, Zhenling Yao, Chetan S. Karyekar, Qing Zuraw
Summary: The long-term efficacy and safety of ustekinumab in patients with active systemic lupus erythematosus was evaluated through a 2-year study. The results showed that ustekinumab led to clinical improvements in global and organ-specific SLE activity measures, with no new or unexpected safety concerns.
JOURNAL OF RHEUMATOLOGY
(2022)
Letter
Immunology
Mark Kacar, Jennifer K. Shrimpton, Miriam Jassam, Anoop Mistry, Gururaj Arumugakani, Alexandros Grammatikos, Mark Gompels, Gina M. Doody, Sinisa Savic
SCANDINAVIAN JOURNAL OF IMMUNOLOGY
(2022)
Article
Rheumatology
Ryo Hisada, Nobuya Yoshida, Seo Yeon K. Orite, Masataka Umeda, Catalina Burbano, Marc Scherlinger, Michihito Kono, Suzanne Krishfield, George C. Tsokos
Summary: The study revealed the crucial role of GLS2 in IL-2 production by CD4+ T cells, as well as its involvement in supporting antioxidant defense. These findings offer a new approach to correcting IL-2 production by T cells in SLE.
ARTHRITIS & RHEUMATOLOGY
(2022)
Letter
Immunology
Alexandros Grammatikos, Philip Bright, Justin Pearson, Marcus Likeman, Mark Gompels
JOURNAL OF CLINICAL IMMUNOLOGY
(2022)
Letter
Allergy
Manisha Ahuja, Anthony Dorr, Eniola Bode, Anne P. R. Boulton, Matthew Buckland, Samuel Chee, Claire Dalley, Sarah Denman, Anjali Ekbote, Shuayb Elkhalifa, Tariq El-Shanawany, Efrem Eren, Archana Herwadkar, Tomaz Garcez, Harichandana Ghanta, Alexandros Grammatikos, Sofia Grigoriadou, Rashmi Jain, Lorena Lorenzo, Ania Manson, Emily Moon, Sai Murng, Aveen Murphy, Leman Mutlu, Nicholas Peters, Kavitha Sooriyakumar, Catherine Stroud, Katie Townsend, Robert L. Yellon, Patrick Yong, Sorena Kiani-Alikhan
Article
Allergy
Fiona Moghaddas, Nikolaos Tsiougkos, Alexandros Grammatikos, Philip D. Bright, Sarah Johnston, Mark Gompels
Summary: This study retrospectively analyzed requests for advice and guidance on COVID-19 vaccine allergy, and evaluated the impact of the advice outcome on vaccination. The majority of patients did not have allergic reactions during vaccination, suggesting that type 1 hypersensitivity is uncommon even in this high-risk population.
WORLD ALLERGY ORGANIZATION JOURNAL
(2023)
Letter
Allergy
Alexandros Grammatikos, Moira Thomas, Sarah Johnston, Fiona Moghaddas, Mahableshwar Albur, Patrick Yong, Matthew Buckland, Sofia Grigoriadou, Andrew F. Whyte, Archana Herwadkar, Mark Gompels
JOURNAL OF ALLERGY AND CLINICAL IMMUNOLOGY-IN PRACTICE
(2023)
Letter
Allergy
Alexandros Grammatikos, Fiona Moghaddas, Paul White, Catherine Fox, Sarah Johnston, Nikolaos Tsiougkos, Mark Gompels
CLINICAL AND EXPERIMENTAL ALLERGY
(2023)
Correction
Immunology
Marc Scherlinger, Christophe Richez, George C. Tsokos, Eric Boilard, Patrick Blanco
NATURE REVIEWS IMMUNOLOGY
(2023)
Review
Immunology
Marc Scherlinger, Christophe Richez, George C. C. Tsokos, Eric Boilard, Patrick Blanco
Summary: Immune-mediated inflammatory diseases (IMIDs) are characterized by excessive and uncontrolled inflammation and thrombosis, both of which are responsible for organ damage, morbidity and death. Platelets play a central role in the pathogenesis and progression of IMIDs, as they are activated by disease-specific factors and promote inflammation and tissue injury. Targeting platelet activation and their interaction with the immune system are promising therapeutic strategies in IMIDs.
NATURE REVIEWS IMMUNOLOGY
(2023)
Correction
Urology & Nephrology
George C. Tsokos, Afroditi Boulougoura, Vivek Kasinath, Yushiro Endo, Reza Abdi, Hao Li
NATURE REVIEWS NEPHROLOGY
(2023)
Review
Urology & Nephrology
George C. Tsokos, Afroditi Boulougoura, Vivek Kasinath, Ushiro Endo, Reza Abdi, Hao Li
Summary: The immune cells and parenchymal cells in the kidney play a significant role in the induction of kidney damage. Kidney parenchymal cells provide structural immunity to the kidney through the regulation of immune-relevant processes, affecting kidney inflammation and injury. Targeted drug delivery to kidney parenchymal cells holds promise for preventing or reversing inflammation in specific forms of kidney injury and disease.
NATURE REVIEWS NEPHROLOGY
(2023)
Article
Immunology
Wenliang Pan, Marc Scherlinger, Nobuya Yoshida, Maria G. Tsokos, George C. Tsokos
Summary: This study demonstrates that PPP2R2D, a regulatory subunit of protein phosphatase 2A, acts as a negative regulator of immune checkpoint receptors. Its absence exacerbates effector T cell exhaustion and promotes regulatory T cell expansion. The expression levels of PPP2R2D are positively correlated with the infiltration of immune cells in melanoma patients.
JOURNAL OF IMMUNOLOGY
(2022)
Article
Immunology
Ryo Hisada, Nobuya Yoshida, Masataka Umeda, Catalina Burbano, Rhea Bhargava, Marc Scherlinger, Michihito Kono, Vasileios C. Kyttaris, Suzanne Krishfield, George C. Tsokos
Summary: SIRT2 suppresses IL-2 production and promotes Th17 cell differentiation, which contributes to the pathogenesis of SLE. SIRT2 activates the mTORC1/HIF-1α/RORγt pathway by deacetylating p70S6K, initiating Th17 cell differentiation. Overexpression of SIRT2 is found in SLE patients, suggesting that SIRT2 may be a potential therapeutic target for SLE.
CELLULAR & MOLECULAR IMMUNOLOGY
(2022)
Meeting Abstract
Allergy
Hadeil Morsi, Alexandros Grammatikos, Cathal Steele, Catherine Stroud, Charu Chopra, Efrem Eren, Emily Moon, Grant Hayman, Harichandana Ghanta, Helen Bourne, John Dempster, Katie Townsend, Manisha Ahuja, Marina Frleta-Gilchrist, Michael Zhang, Moira Thomas, Richard Herriot, Sai Murng, Sara Drinkwater, Suzanne Elcombe, Tanya Coulter, Tariq El-shanawany, Tomaz Garcez, Patrick Yong, Rashmi Jain
JOURNAL OF ALLERGY AND CLINICAL IMMUNOLOGY
(2022)